SCHEMBL6170956

SCHEMBL6170956

COc1cc(-c2cccc(OC(C)C)c2)c2cc(Br)ccc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.47
MAPT P10636 5/20 0.44
ATM Q13315 1/20 0.44
PRNP P04156 1/20 0.43
LTB4R Q15722 1/20 0.42
PTGFR P43088 5/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAP4K4 O95819 1/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
GABRA1 P14867 2/20 0.39
GABRG2 P18507 2/20 0.39
GABRB3 P28472 2/20 0.39
GABRA5 P31644 2/20 0.39
GABRA3 P34903 2/20 0.39
CLK1 P49759 1/20 0.39
CDK5 Q00535 1/20 0.39
CDK5R1 Q15078 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6171945 0.89 MAPT (0.50) L3MBTL1MAPTPRNPLTB4RPTGFR
SCHEMBL25224251 0.86 L3MBTL1 (0.43) L3MBTL1MAPTATMPRNPLTB4R
SCHEMBL30533422 0.86 L3MBTL1 (0.43) L3MBTL1MAPTATMPRNPLTB4R
SCHEMBL30533423 0.86 L3MBTL1 (0.43) L3MBTL1MAPTATMPRNPLTB4R
SCHEMBL6170480 0.84 LTB4R (0.45) L3MBTL1MAPTPRNPLTB4RMEN1
SCHEMBL14570639 0.82 PRNP (0.57) L3MBTL1MAPTATMPRNPLTB4R
SCHEMBL26565172 0.82 L3MBTL1 (0.49) L3MBTL1MAPTATMPRNPPTGFR
SCHEMBL6172146 0.81 L3MBTL1 (0.51) L3MBTL1MAPTATMPRNPLTB4R
SCHEMBL1757872 0.81 MEN1 (0.49) L3MBTL1MAPTPRNPLTB4RPTGFR
SCHEMBL26564752 0.79 L3MBTL1 (0.49) L3MBTL1MAPTATMPRNPLTB4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1150973-B1 HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PROD INC (US) 2005-06-15 EP disclosed
US-6710209-B2 INHIBITING FARNESYL PROTEIN TRANSFERASE. PFIZER INC 2004-03-23 US disclosed
US-20020120145-A1 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents PFIZER INC. 2002-08-29 US disclosed
US-6388092-B2 ANTITUMOR AGENT PFIZER INC 2002-05-14 US disclosed
US-20020019530-A1 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents YANG BINGWEI V (US) 2002-02-14 US disclosed
EP-1150973-A1 HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2001-11-07 EP disclosed
US-6258824-B1 TREATMENT OF HYPERPROLIFERATIVE DISEASES, SUCH AS CANCERS, IN MAMMALS. THIS INVENTION ALSO RELATES TO A PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS. PFIZER INC. 2001-07-10 US disclosed
WO-2000047574-A1 HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 2000-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120145-A1 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents NRAS, CCNA1, KRAS L3MBTL1 355/4885MAPT 4805/4885ATM 4191/4885
US-20020019530-A1 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents NRAS, CCNA1, KRAS L3MBTL1 355/4885MAPT 4805/4885ATM 4191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.